BioSpace News Archive

The report highlights the trends prevalent in the global digital pathology market and the factors driving the market along with those that act as drivers to its growth.

CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, today announced that Ramin Mousavi has been appointed Chief Executive Officer, effective June 21, 2021.

The market is estimated to grow with a CAGR of 7.7% from 2019-2027. The report highlights the trends prevalent in the global transradial access market and the factors driving the market along with those that act as deterrents to its growth.

MedinCell and the consortium members have conducted an in vivo proof of concept on cattle that showed a 3-month mosquitocidal effectiveness of an injectable long-acting formulation of Ivermectin based on the proprietary BEPO® technology.

Certain patients with an aggressive form of ovarian cancer have a better chance of a cure through surgical removal of their tumor before chemotherapy instead of the reverse, a new study shows.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that its shareholders, at its meeting on June 9, 2021, elected Milton Morris, PhD, as Director.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Sandra Milligan, M.D., J.D., to its Board of Directors.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.

Increasing focus on personalized medicines and technological advancements in radiotracers will drive market growth.